A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
7 Hills Pharma, LLC
Genmab
Aulos Bioscience, Inc.
Obsidian Therapeutics, Inc.
Hoffmann-La Roche
M.D. Anderson Cancer Center
AstraZeneca
Mayo Clinic
BioNTech SE
Neonc Technologies, Inc.
Hummingbird Bioscience
Arvinas Inc.
M.D. Anderson Cancer Center
Essen Biotech
Essen Biotech
University of California, Davis
Beijing Tide Pharmaceutical Co., Ltd
M.D. Anderson Cancer Center
Second Life Therapeutics
Onchilles Pharma Inc
M.D. Anderson Cancer Center
Linnaeus Therapeutics, Inc.
Inhibrx Biosciences, Inc
GV20 Therapeutics
Transgene
DualityBio Inc.
Revolution Medicines, Inc.
University of Pittsburgh
University of Arizona
Hadassah Medical Organization
Hadassah Medical Organization
Incyte Corporation
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Incyte Corporation
Incyte Corporation
Cancer Research UK
MacroGenics
NuCana plc
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
OncoC4, Inc.
Mural Oncology, Inc
Rapa Therapeutics LLC
Xynomic Pharmaceuticals, Inc.
Kymab Limited
Syndax Pharmaceuticals
Sarcoma Oncology Research Center, LLC